Amy L. Dunn

Amy L. Dunn

Auto-generated profile, based on publicly available information

Amy L. Dunn

Nationwide Children’s Hospital, Division of Pediatric Hematology, Oncology and Bone Marrow Transplant

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2015 in Nano Letters
Verified
Journal Article
Closed access
BLBin Li
Bin Li
XLXiao Luo
Xiao Luo
BDBinbin Deng
Binbin Deng
JWJunfeng Wang
Junfeng Wang
DMDavid W. McComb
David W. McComb
YDYizhou Dong
Yizhou Dong

5 July 2012 in Haemophilia
Verified
Journal Article
Closed access
PDF file
BLB. Lundin
B. Lundin
MMM. L. Manco‐Johnson
M. L. Manco‐Johnson
DIDanial Ignas
Danial Ignas
RMR. Moineddin
R. Moineddin
VBV. S. Blanchette
V. S. Blanchette
TGThe International Prophylaxis Study Group
The International Prophylaxis Study Group

3 June 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
BWBeth Boulden Warren
Beth Boulden Warren
DTDianne Thornhill
Dianne Thornhill
JSJill Stein
Jill Stein
MFMichael Fadell
Michael Fadell
JIJ. David Ingram
J. David Ingram
MMMarilyn J. Manco-Johnson
Marilyn J. Manco-Johnson
The Joint Outcome Study (JOS), a randomized controlled trial, demonstrated that children with severe hemophilia A (HA) initiating prophylactic factor VIII (FVIII) prior to age 2.5 years had reduced joint damage at age 6 years compared with those treated with episodic FVIII for bleeding. The Joint Outcome Continuation Study (JOS-C) evaluated early vs delayed prophylaxis effects on long-term joint health, following JOS participants to age 18 years in an observational, partially retrospective study. Index joint magnetic resonance imaging (MRI) scores of osteochondral (OC) damage (primary outcome), joint physical examination scores, and annualized rates of joint/other bleeding episodes (secondary outcomes) were collected. Thirty-seven of 65 JOS participants enrolled in JOS-C, including 15 randomized to prophylaxis at mean age 1.3 years (“early prophylaxis”); 18 initially randomized to episodic treatment, starting “delayed prophylaxis” at mean age 7.5 years; and 4 with high-titer inhibitors. At JOS-C exit, MRI OC damage was found in 77% of those on delayed and 35% of those on early prophylaxis for an odds ratio of OC damage, in the delayed vs early prophylaxis group, of 6.3 (95% confidence interval, 1.3, 29.9; P = .02). Annualized bleeding rates were higher with delayed prophylaxis (mean plus or minus standard deviation, 10.6 ± 6.6 vs 3.5 ± 2.1; P < .001), including when only comparing time periods on prophylaxis (6.2 ± 5.3 vs 3.3 ± 1.9; P < .05). In severe HA, early initiation of prophylaxis provided continued protection against joint damage throughout childhood compared with delayed initiation, but early prophylaxis was not sufficient to fully prevent damage. This trial was registered at www.clinicaltrials.gov as #NCT01000844.

15 September 2016 in Haemophilia
Verified
Journal Article
Open access
PDF file
KFK. Fischer
K. Fischer
PPP. Poonnoose
P. Poonnoose
ADA. L. Dunn
A. L. Dunn
PBP. Babyn
P. Babyn
MMM. J. Manco‐Johnson
M. J. Manco‐Johnson
TAthe participants of the International Symposium on Outcome Measures in Hemophilic Arthropathy
the participants of the International Symposium on Outcome Measures in Hemophilic Arthropathy
Introduction: The implementation of early long‐term, regular clotting factor concentrate (CFC) replacement therapy (‘prophylaxis’) has made it possible to offer boys with haemophilia a near normal life. Many different regimens have reported favourable results, but the optimum treatment regimens have not been established and the cost of prophylaxis is very high. Both for optimizing treatment and reimbursement issues, there is a need to provide objective evidence of both short‐ and long‐term results and benefits of prophylactic regimens.Aims: This report presents a critical review of outcome measures for use in the assessment of musculoskeletal health in persons with haemophilia according to the International Classification of Functioning, Disability and Health (ICF). This framework considers structural and functional changes, activities and participation in a context of both personal and environmental factors.Methods: Results were generated by a combination of a critical review of available literature plus expert opinion derived from a two day consensus conference between 48 health care experts from different disciplines involved in haemophilia assessment and care. Outcome tools used in haemophilia were reviewed for reliability and validity in different patient groups and for resources required.Results and conclusion: Recommendations for choice of outcome tools were made according to the ICF domains, economic setting, and reason for use (clinical or research). The next step will be to identify a ‘core’ set of outcome measures for use in clinical care or studies evaluating treatment.

1 January 2004 in Journal of Pediatric Orthopaedics
Verified
Journal Article
Closed access
ADAmy L. Dunn
Amy L. Dunn
MBMichael T. Busch
Michael T. Busch
JWJ. Bradley Wyly
J. Bradley Wyly
KSKevin M. Sullivan
Kevin M. Sullivan
TAThomas C. Abshire
Thomas C. Abshire

12 July 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
NANadine G. Andersson
Nadine G. Andersson
GAGünter Auerswald
Günter Auerswald
CBChris Barnes
Chris Barnes
MCManuel Carcao
Manuel Carcao
ADAmy L. Dunn
Amy L. Dunn
RLRolf Ljung
Rolf Ljung